Vaderis Therapeutics
PrivateLast Round
Series B
Aug 11, 2026
Total Funding Raised
$189.1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Vaderis Therapeutics is a biotechnology company that develops targeted therapies for rare vascular diseases, with a primary focus on hereditary hemorrhagic telangiectasia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vaderis Therapeutics Comparables
Compare Vaderis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BridgeBio | 77% | |
| Novartis | 72% | |
| Neurelis | 72% | |
Vaderis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 11, 2026 | ||||
| Series A | May 1, 2020 | ||||
| Series A | Apr 1, 2020 |
Key People
Founding team and executive leadership
Vaderis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TCG Crossover | Series B |
| Omega Funds | Series B |
| EQT Life Sciences | Series B |
| Perceptive Advisors | Series B |
| Life Sciences at Goldman Sachs Alternatives | Series B |
| Droia Ventures | Series B, Series A |
| Kalehua Capital Management | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 18, 2026
Monthly visitors increased 75% MoM.
- Feb 18, 2026
Grew 21% QoQ from 14 to 17 employees.
Vaderis Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Vaderis Therapeutics's valuation, stock price, and market status.